arrow
Return

Tuberous sclerosis complex

delete2016-05-26
delete479
PRE
AI
E
Elizabeth P. Henske *
S
Sergiusz Jóźwiak
J
J.C. Kingswood
J
Julian R. Sampson
E
Elizabeth A. Thiele
DOI:10.1038/nrdp.2016.35delete
deleteOriginal
deleteShare
deleteSave
Abstract

Abstract

En 中文
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder that affects multiple organ systems and is caused by loss-of-function mutations in one of two genes: TSC1 or TSC2. The disorder can affect both adults and children. First described in depth by Bourneville in 1880, it is now estimated that nearly 2 million people are affected by the disease worldwide. The clinical features of TSC are distinctive and can vary widely between individuals, even within one family. Major features of the disease include tumours of the brain, skin, heart, lungs and kidneys, seizures and TSC-associated neuropsychiatric disorders, which can include autism spectrum disorder and cognitive disability. TSC1 (also known as hamartin) and TSC2 (also known as tuberin) form the TSC protein complex that acts as an inhibitor of the mechanistic target of rapamycin (mTOR) signalling pathway, which in turn plays a pivotal part in regulating cell growth, proliferation, autophagy and protein and lipid synthesis. Remarkable progress in basic and translational research, in addition to several randomized controlled trials worldwide, has led to regulatory approval of the use of mTOR inhibitors for the treatment of renal angiomyolipomas, brain subependymal giant cell astrocytomas and pulmonary lymphangioleiomyomatosis, but further research is needed to establish full indications of therapeutic treatment. In this Primer, we review the state-of-the-art knowledge in the TSC field, including the molecular and cellular basis of the disease, medical management, major knowledge gaps and ongoing research towards a cure.
Keywords:
POLYCYSTIC KIDNEY-DISEASE
GIANT-CELL ASTROCYTOMA
SPORADIC PULMONARY LYMPHANGIOLEIOMYOMATOSIS
MICRONODULAR PNEUMOCYTE HYPERPLASIA
TSC CLINICAL RECOMMENDATIONS
AUTISM SPECTRUM DISORDERS
RENAL ANGIOMYOLIPOMA
MAMMALIAN TARGET
NATURAL-HISTORY
MOUSE MODEL

Journal

N
Nature Reviews Disease Primers
IF:
60.6
Papers:
663
Citations:
4.8W

Organization

U
university of brighton
Scholars:
85
Papers: 52
Citations: 2.4K
M
Medical University of Warsaw
Scholars:
471
Papers: 180
Citations: 2.7K
H
Harvard University
Scholars:
7.2K
Papers: 2.5K
Citations: 20.7W
researcher View more organizations
Cited Papers

Cited Papers

errShare
errSave
Relationship of perfusion to edema in the 9L gliosarcoma
err1993-04-01
err0
PREAI
errR. Grant Steen; Sharon Kromhout-Schiro; Michael M. Graham
errShare
errSave
errShare
errSave
err
IF0
err
err0
PREAI
err
errShare
errSave
Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex
errBRAIN
IF11.7
err2002-06-01
err229
errOAAI
errBolton, PF; Park, RJ; Higgins, JNP; Griffiths, PD; Pickles, A
errShare
errSave
Everolimus alters white matter diffusion in tuberous sclerosis complex
err2012-02-21
err63
PREAI
errTillema, Jan-Mendelt; Leach, James L.; Krueger, Darcy A.; Franz, David Neal
errShare
errSave
researcher View more